ArticleNeurosurgery2015
The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma.
Article in Neurosurgery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update.Journal of neuro-oncology · 2020Pooled it
- Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of chemotherapeutic management and antiangiogenic treatment of newly diagnosed glioblastoma in adults.Journal of neuro-oncology · 2020Pooled it
- The Impact of Timing of Concurrent Chemoradiation in Patients With High-Grade Glioma in the Era of the Stupp Protocol.Frontiers in oncology · 2019Pooled it
- Trial
- Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.Frontiers in immunology · 2018Trial
- Enhanced recovery after surgery (ERAS) for elective glioma craniotomy: a propensity score-matched retrospective cohort study.Neurosurgical review · 2026Article
- Optimal timing of chemoradiation after resection or biopsy of glioblastomas: a nationwide population-based study.BMC cancer · 2024Article
- The impact of cancer patient pathway on timing of radiotherapy and survival: a cohort study in glioblastoma patients.Journal of neuro-oncology · 2024Article
- Does waiting for surgery matter? How time from diagnostic MRI to resection affects outcomes in newly diagnosed glioblastoma.Journal of neurosurgery · 2024Article
- Impact of timing to initiate adjuvant therapy on survival of elderly glioblastoma patients using the SEER-Medicare and national cancer databases.Scientific reports · 2023Article
- Impact of Rural vs. Urban Residence on Survival Rates of Patients with Glioblastoma: A Tertiary Care Center Experience.Brain sciences · 2022Article
- Optimal timing of radiotherapy following brain metastases surgery.Neuro-oncology practice · 2022Article
- Time to treatment initiation and outcomes in high-grade glioma patients in rehabilitation: a retrospective cohort study.CNS oncology · 2020Article
- Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study.Journal of neuro-oncology · 2019Article
- The impact of the time to start radiation therapy on overall survival in newly diagnosed glioblastoma.Journal of neuro-oncology · 2019Article
- Impact of time to initiation of radiotherapy on survival after resection of newly diagnosed glioblastoma.Radiation oncology (London, England) · 2019Article
- Newly Diagnosed Glioblastoma: A Review on Clinical Management.Oncology (Williston Park, N.Y.) · 2019Review
- Survival impact of prolonged postoperative radiation therapy for patients with glioblastoma treated with combined-modality therapy.Neuro-oncology practice · 2019Article
- Survival Impact of Delaying Postoperative Radiotherapy in Patients with Esophageal Cancer.Translational oncology · 2018Article
- Survival impact of postoperative radiotherapy timing in pediatric and adolescent medulloblastoma.Neuro-oncology · 2018Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe effect of timing of initiation of concurrent radiation and chemotherapy after surgery on outcome of patients with glioblastoma (GBM) remains unclear.
objectiveTo further explore this issue, we analyzed 4 clinical trials for patients newly diagnosed with GBM receiving concurrent and adjuvant temozolomide.
methodsThe cohort study included 198 adult patients with newly diagnosed supratentorial GBM who were enrolled from 2004 to 2010 in 4 clinical trials consisting of radiation plus temozolomide and an experimental agent. The interval to initiation of therapy was determined from the time of surgical resection. The partitioning deletion/substitution/addition algorithm was used to determine the cutoff points for timing of chemoradiation at which there was a significant difference in overall survival (OS) and progression-free survival (PFS).
resultsThe median wait time between surgery and initiation of concurrent chemoradiation was 29.5 days (range, 7-56 days). A short delay in chemoradiation administration (at 30-34 days) was predictive of prolonged OS (hazard ratio [HR]: 0.63, P = .03) and prolonged PFS (HR: 0.68, P = .06) compared with early initiation of concurrent chemoradiation (<30 days), after adjusting for protocol and baseline prognostic variables including extent of resection by multivariate analysis. A longer delay to chemoradiation beyond 34 days was not associated with improved OS or PFS compared with early initiation (HR: 0.94, P = .77 and HR: 0.91, P = .63, respectively).
conclusionA short delay in the start of concurrent chemoradiation is beyond the classic paradigm of 4 weeks post-resection and may be associated with prolonged OS and PFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.